United Therapeutics Corporation (UTHR)UTHRUnited Therapeutics Corporation

SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
4	Jul 27, 2026	Jul 27, 2026	View filing
4	Jul 27, 2026	Jul 27, 2026	View filing
4	Jul 24, 2026	Jul 24, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
3	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 23, 2026	Jul 23, 2026	View filing
8-K	Jul 23, 2026	Jul 23, 2026	View filing
4	Jul 22, 2026	Jul 22, 2026	View filing
4	Jul 21, 2026	Jul 21, 2026	View filing
4	Jul 20, 2026	Jul 20, 2026	View filing
4	Jul 17, 2026	Jul 17, 2026	View filing
4	Jul 16, 2026	Jul 16, 2026	View filing
4	Jul 16, 2026	Jul 16, 2026	View filing
4	Jul 15, 2026	Jul 15, 2026	View filing
4	Jul 14, 2026	Jul 14, 2026	View filing
4	Jul 13, 2026	Jul 13, 2026	View filing
4	Jul 13, 2026	Jul 13, 2026	View filing
4	Jul 13, 2026	Jul 13, 2026	View filing
4	Jul 13, 2026	Jul 13, 2026	View filing

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Silver Spring, MD

1,400 employees

www.unither.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Martine A. Rothblatt

View full financials